I don't know where you are getting this view that the tests were inconclusive. These were the published results from the blind test you talked about supposedly disproving the technology.......
Scientific research to date
International Journal of Cancer 2005
Clinical Studies 503 blinded samples: Results: No False Negatives: All positive samples were correctly identified, 86% negatives correct, 14% false positives but some of these individuals were later confirmed to have breast cancer.
Technology outcomes • The diffraction “ring” can be detected at an early stage in tumour growth. • Trials with over 1300 blinded samples yielded no false negatives. • Tests have shown potential in initial trials (Breast, Prostate, Colon, Lung, Melanoma and also Alzheimer's disease). • The results demonstrate that x-ray diffraction of hair offers an alternative screening test for breast cancer. • X-ray diffraction of hair is non-invasive and totally “patient friendly”. Note: This research received support from the Commonwealth of Australia through the Access to the Major Research Facilities Program and the Australian Synchrotron Research Program.
Why Fermiscan will be successful?
Building strategic relationships within the Medical groups and Government bodies
Radiologists, Pathologists, GP’s, National Breast Cancer bodies and key Associations.
Launch plan based on steps
Test Pilot Review and modify Market release
Medical endorsement through joint participation, distribution and development of processes.
Build knowledge and understanding of patient, Specialists and GP needs during the process.
AVS and FER are my top picks for 2007
FER Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held